Zynyz Approved for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma
The FDA has granted accelerated approval to Zynyz (retifanlimab) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
Diagnosis & Disease Information
Pentagon Study Finds Higher Cancer Rates Among Pilots, Ground Crews
Military pilots and the ground crews who fuel and maintain their aircraft have higher rates of certain cancers, a new study shows.
Adverse Birth Outcomes More Common Among AYAs With Cancer During Pregnancy
Adolescent and young adult patients diagnosed with cancer during pregnancy have a higher risk of adverse birth outcomes, a study suggests.
Comparable Outcomes With and Without Neoadjuvant Therapy in High-Risk Melanoma
Patients with high-risk, stage III melanoma have similar outcomes whether they undergo surgery upfront or receive immunotherapy prior to surgery, a study suggests.
Nicotinamide Does Not Prevent Keratinocyte Cancers in Organ Recipients
Oral nicotinamide does not reduce the risk of keratinocyte cancers in organ transplant recipients, a study suggests.
Basal Cell Carcinoma: A Review
Authors present a concise overview of the diagnosis, risk factors, and treatment of basal cell carcinoma.
Personalized ctDNA Monitoring Can Predict Outcomes in Advanced Melanoma
Personalized ctDNA monitoring can predict outcomes during and after treatment in patients with advanced melanoma, a study suggests.
Certain Antibiotics May Reduce the Efficacy of Certain ICIs in Cancer Patients
A new study suggests that fluoroquinolones — but not other antibiotics — may reduce the efficacy of certain ICIs in certain cancers.
Periadjuvant Pembrolizumab Improves EFS in Resectable Melanoma
Periadjuvant pembrolizumab may improve outcomes over adjuvant pembrolizumab alone in patients with resectable stage III-IV melanoma, a phase 2 study suggests.
Novel Treatment Approach May Reduce Risk of Death From ICI-Related Myocarditis
A novel method of treating immune checkpoint inhibitor-associated myocarditis may decrease the risk of death from myotoxicity.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...